By Judith Gicobi
Kenya has made an agreement with Moderna to build the company’s first production facility in Africa.
Susan Mochache, the Principal Secretary of Health, released a statement on Monday.
President Uhuru Kenyatta said Kenya is “pleased to partner with Moderna in the establishment of this mRNA manufacturing facility to help prepare the country and our sister states on the continent through the African Union to respond to future health crises and stave off the next pandemic.”
Kenyatta described the relationship as a testament to “our community and our commitment to technological innovation. Moderna’s investment in Kenya will help advance equitable global vaccine access and is emblematic of the structural developments that will enable Africa to become an engine of sustainable global growth.”
Health Cabinet Secretary Mutahi Kagwe said, “Kenya recognizes and appreciates the collaboration of Moderna in building our local manufacturing capacity. This will ensure as a country and region we can quickly respond to health demands requiring Vaccine commodities.”
“We would like to thank the Government of the Republic of Kenya for their support in bringing our mRNA manufacturing facility to Kenya. We would also like to thank the U.S. Government for assisting us in this process. We are honored to have played such a critical role in combatting the COVID-19 pandemic with our vaccine and we are determined to expand our global impact with our first manufacturing facility on the continent of Africa.” Stated Noubar Afeyan, Co-founder and Chairman of Moderna.
Moderna’s mRNA pipeline contains 28 vaccine products in their preventative vaccinations modality, comprising vaccines against viral pathogens, vaccinations against cryptic viral infections, and vaccinations targeting worldwide public health threats.